The ratings of 4 Life Sciences Tools & Services stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Bio-Rad Laboratories, Inc. Class A’s (BIO) rating weakens this week, dropping to a D versus last week’s C. Bio-Rad Laboratories, Inc. Class A manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with products and systems used to separate complex chemical and biological materials and to identify, analyze, and purify their components. The company also gets F’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of BIO stock.
This week, QIAGEN NV’s (QGEN) rating worsens to a D from the company’s C rating a week ago. QIAGEN NV provides sample and assay technologies. For more information, get Portfolio Grader’s complete analysis of QGEN stock.
This is a rough week for pSivida Corp. (PSDV). The company’s rating falls to D from the previous week’s C. PSivida Corp. develops drug delivery products for treatment of back-of-the-eye diseases that are administered by implantation, injection, or insertion. The company also gets F’s in operating margin growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PSDV stock.
Harvard Bioscience, Inc. (HBIO) earns a F this week, moving down from last week’s grade of D. Harvard Bioscience, Inc. develops, manufactures, and markets tools used in drug discovery research and pharmaceutical and biotechnology companies, universities, and government laboratories. The company also gets F’s in operating margin growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of HBIO stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.